Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214779) titled 'Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression' on Oct. 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Incyte Corporation
Condition:
Ovarian Cancer
Intervention:
Drug: INCB123667
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: December 1, 2025
Target Sample Size: 466
To know more, visit https://clinicaltrials.gov/study/NCT07214779
...